Figure 3
From: Development of a novel small antibody that retains specificity for tumor targeting
The competition ability of synthetic V H FR1 C-10 -V H CDR1-V H FR2-V L CDR3-V L FR4 N-10 . (a) Fixed MCF-7 cells were incubated with PBS, LWMP, Fab, PMN and Sc-Fv peptides (50 μM) and DAPI (50 ng/ml) prior to flow cytometry. LWMP, low molecular weight marker protein; Fab, Fab segment from original antibody; PMN, protomimecin; Sc-Fv, ScFv segment from original antibody. (b) The relative affinity of VHFR1C-10-VHCDR1-VHFR2-VLCDR3-VLFR4N-10 peptides and OAbs to antigen. OAb, original antibody. (c) Concentration-dependent inhibition of different concentration of synthetic mimetic antibody or OAb against 75 μg/ml PMN. (d) MCF-7 cell survival ratio of the inhibition activity of OAb against PMN (75 μg/ml). OAb, original mAb antibody A520C9.